Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.030 -0.060 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
News headline image
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update ↗
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). 
Via Benzinga
News headline image
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week... 
Via Talk Markets
News headline image
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From atai Life Sciences
Via GlobeNewswire
News headline image
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years ↗
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
News headline image
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks In Decline ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. 
Via Talk Markets
News headline image
atai Life Sciences to Participate in Upcoming September Investor Conferences
From atai Life Sciences
Via GlobeNewswire
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
Via Talk Markets
News headline image
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
News headline image
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15% ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
Via Talk Markets
News headline image
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
News headline image
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week ↗
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
Via Talk Markets
News headline image
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
News headline image
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
News headline image
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
News headline image
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
News headline image
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA ↗
Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show: 
Via Benzinga
News headline image
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
From atai Life Sciences
Via GlobeNewswire
News headline image
Atai's Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration ↗
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) shared results from majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of its... 
Via Benzinga
News headline image
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
News headline image
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
News headline image
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average ↗
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
News headline image
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
News headline image
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD ↗
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD. 
Via Talk Markets
News headline image
Psychedelic Stocks Jumped 10% Last Week ↗
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly 
Via Talk Markets
News headline image
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital ↗
Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist 
Via Benzinga
News headline image
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
Via Talk Markets
News headline image
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.